International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction
- PMID: 25406306
- DOI: 10.1161/CIRCULATIONAHA.114.012284
International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction
Abstract
Background: International geographic differences in outcomes may exist for clinical trials of heart failure and reduced ejection fraction (HF-REF), but there are few data for those with preserved ejection fraction (HF-PEF).
Methods and results: We analyzed outcomes by international geographic region in the Irbesartan in Heart Failure with Preserved systolic function trial (I-Preserve), the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM)-Preserved trial, the CHARM-Alternative and CHARM-Added HF-REF trials, and the Controlled Rosuvastatin Multinational Trial in HF-REF (CORONA). Crude rates of heart failure hospitalization varied by geographic region, and more so for HF-PEF than for HF-REF. Rates in patients with HF-PEF were highest in the United States/Canada (HF hospitalization rate 7.6 per 100 patient-years in I-Preserve; 8.8 in CHARM-Preserved), intermediate in Western Europe (4.8/100 and 4.7/100), and lowest in Eastern Europe/Russia (3.3/100 and 2.8/100). The difference between the United States/Canada versus Eastern Europe/Russia persisted after adjustment for key prognostic variables: adjusted hazard ratios 1.34 (95% confidence interval, 1.01-1.74; P=0.04) in I-Preserve and 1.85 (95% confidence interval, 1.17-2.91; P=0.01) in CHARM-Preserved. In HF-REF, rates of HF hospitalization were slightly lower in Western Europe compared with other regions. For both HF-REF and HF-PEF, there were few regional differences in rates of all-cause or cardiovascular mortality.
Conclusions: The differences in event rates observed suggest there is international geographic variation in 1 or more of the definition and diagnosis of HF-PEF, the risk profile of patients enrolled, and the threshold for hospitalization, which has implications for the conduct of future global trials.
Keywords: heart failure; hospitalization; mortality; ventricular ejection fraction.
© 2014 American Heart Association, Inc.
Comment in
-
Regional differences in heart failure with preserved ejection fraction trials: when nephrology meets cardiology but east does not meet west.Circulation. 2015 Jan 6;131(1):7-10. doi: 10.1161/CIRCULATIONAHA.114.013637. Epub 2014 Nov 18. Circulation. 2015. PMID: 25406307 No abstract available.
Similar articles
-
The effect of renin-angiotensin system inhibitors on mortality and heart failure hospitalization in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis.J Card Fail. 2010 Mar;16(3):260-7. doi: 10.1016/j.cardfail.2009.11.007. Epub 2010 Jan 6. J Card Fail. 2010. PMID: 20206902
-
What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE?J Am Coll Cardiol. 2012 Dec 11;60(23):2349-56. doi: 10.1016/j.jacc.2012.04.064. Epub 2012 Nov 7. J Am Coll Cardiol. 2012. PMID: 23141494 Review.
-
Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity).J Am Coll Cardiol. 2013 Nov 12;62(20):1845-54. doi: 10.1016/j.jacc.2013.05.072. Epub 2013 Jul 10. J Am Coll Cardiol. 2013. PMID: 23850914
-
Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials.JACC Heart Fail. 2020 Aug;8(8):618-626. doi: 10.1016/j.jchf.2020.02.007. Epub 2020 May 6. JACC Heart Fail. 2020. PMID: 32387067 Clinical Trial.
-
Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE).Circ Heart Fail. 2011 Jan;4(1):27-35. doi: 10.1161/CIRCHEARTFAILURE.109.932996. Epub 2010 Nov 10. Circ Heart Fail. 2011. PMID: 21068341 Clinical Trial.
Cited by
-
Trends in prevalence of comorbidities in heart failure clinical trials.Eur J Heart Fail. 2020 Jun;22(6):1032-1042. doi: 10.1002/ejhf.1818. Epub 2020 Apr 15. Eur J Heart Fail. 2020. PMID: 32293090 Free PMC article.
-
Epidemiology and Clinical Features of Heart Failure with Preserved Ejection Fraction.Card Fail Rev. 2022 Aug 4;8:e27. doi: 10.15420/cfr.2022.06. eCollection 2022 Jan. Card Fail Rev. 2022. PMID: 35991117 Free PMC article. Review.
-
Geographical Variations in Patients with Heart Failure and Preserved Ejection Fraction: A Sub-Group Analysis of the APOLLON Registry.Balkan Med J. 2019 Jul 11;36(4):235-244. doi: 10.4274/balkanmedj.galenos.2019.2019.2.17. Epub 2019 Apr 4. Balkan Med J. 2019. PMID: 30945522 Free PMC article.
-
Factors associated with hospitalisations of patients with chronic heart failure approaching the end of life: A systematic review.Palliat Med. 2022 Dec;36(10):1452-1468. doi: 10.1177/02692163221123422. Epub 2022 Sep 28. Palliat Med. 2022. PMID: 36172637 Free PMC article.
-
Reporting trends of randomised controlled trials in heart failure with preserved ejection fraction: a systematic review.Open Heart. 2016 Aug 1;3(2):e000449. doi: 10.1136/openhrt-2016-000449. eCollection 2016. Open Heart. 2016. PMID: 27547434 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous